scholarly journals Efficacy and Safety of Botulinum Toxin A for Treating Bladder Hyperactivity in Children and Adolescents with Neuropathic Bladder Secondary to Myelomeningocele

2013 ◽  
Vol 2013 ◽  
pp. 1-5
Author(s):  
Antonio Marte ◽  
Micaela Borrelli ◽  
Maurizio Prezioso ◽  
Lucia Pintozzi ◽  
Pio Parmeggiani
Keyword(s):  
Botulinum Toxin ◽  
Neurogenic Bladder ◽  
Botulinum Toxin A ◽  
Invasive Procedure ◽  
Bladder Capacity ◽  
Rank Test ◽  
Clean Intermittent Catheterization ◽  
Efficacy And Safety ◽  
Average Increase ◽  
Toxin A

We verified the efficacy and safety of botulinum toxin A (BTX-A) in treating bladder overactivity in children with neurogenic bladder (NB) secondary to myelomeningocele (MMC). Forty-seven patients (22, females; 25, males; age range, 5–17 years; mean age, 10.7 years) with poorly compliant/overactive neurogenic bladder on clean intermittent catheterization (CIC) and resistance or noncompliant to anticholinergics were injected with 200 IU of BTX-A intradetrusor. All patients experienced a significant 66.45% average increase of leak point volume (Wilcoxon paired rank test = 7.169 e-10) and a significant 118.57% average increase of specific bladder capacity at 20 cm H2O (Wilcoxon paired rank test = 2.466 e-12). Ten patients who presented with concomitant uni/bilateral grade II–IV vesicoureteral reflux were treated at the same time with Deflux. No patient presented with major perioperative or postoperative problems. Twenty-two patients needed a second and 18 a third injection of BTX-A after 6–9 months for the reappearance of symptoms. After a mean follow-up of 5.7 years, 38 out of 47 patients achieved dryness between CICs, and 9 patients improved their incontinence but still need pads. Our conclusion is that BTX-A represents a viable alternative to more invasive procedure in treatment of overactive NB secondary to MMC.

1125: Botulinum Toxin a in Neurogenic Bladder: Are there any Patient Predictors of Response?

2005 ◽  
Vol 173 (4S) ◽  
pp. 305-305
Author(s):  
Brigitte Schurch ◽  
Marianne de Seze ◽  
Pierre Denys ◽  
Emmanuel Chartier-Kastler ◽  
Francois Haab ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Neurogenic Bladder ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Predictors Of Response

scholarly journals Botulinum Toxin-A Therapy in Pediatric Urology: Indications for the Neurogenic and Non-Neurogenic Neurogenic Bladder

2009 ◽  
Vol 9 ◽  
pp. 1300-1305 ◽  
Author(s):  
Lori Dyer ◽  
Israel Franco
Keyword(s):  
Botulinum Toxin ◽  
Neurogenic Bladder ◽  
Botulinum Toxin A ◽  
Sensory Nerve ◽  
Nerve Fibers ◽  
Review Article ◽  
Pediatric Urology ◽  
Urethral Sphincter ◽  
Toxin A

Although, the role of Botulinum Toxin-A in the treatment of the neurogenic and non-neurogenic neurogenic bladder is becoming more defined, this is the first review article to characterize the emerging role of Botulinum Toxin-A in the pediatric urologic population. Injection of Botulinum Toxin-A at the level of the bladder works by inhibiting uninhibited bladder contractions and, possibly, by blocking some of the sensory nerve fibers. In children with sphincter dyssynergy, injection at the level of the urethral sphincter works by inhibiting the involuntary guarding reflex and blocking dyssynergic voiding.

Repeated Injection of Botulinum Toxin a in Patients with Neurogenic Bladder: Our Experience

2012 ◽  
Vol 79 (19_suppl) ◽  
pp. 9-14
Author(s):  
Ubaldo Cantoro ◽  
Daniele Minardi ◽  
Vito Lacetera ◽  
Alessandro Conti ◽  
Francesco Catanzariti ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Neurogenic Bladder ◽  
Botulinum Toxin A ◽  
Repeated Injection ◽  
Toxin A

scholarly journals A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients

Toxins ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 365 ◽  
Author(s):  
Yi-Huei Chang ◽  
Po-Jen Hsiao ◽  
Huang Chi-Ping ◽  
Hsi-Chin Wu ◽  
Po-Fan Hsieh ◽  
...  
Keyword(s):  
Urinary Incontinence ◽  
Botulinum Toxin ◽  
Adverse Events ◽  
Observational Study ◽  
Botulinum Toxin A ◽  
Mixed Urinary Incontinence ◽  
Efficacy And Safety ◽  
Toxin A ◽  
Antimuscarinic Agent ◽  
Significant Difference

This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients received MUS only and MUS with BoNT-A injection, respectively. The efficacy outcome included change in Urinary Incontinence Outcome Scores (UIOS), change in Overactive Bladder Symptom Score (OABSS), and use of antimuscarinic agent or beta-3 agonist. Safety assessments included adverse events including urinary retention, increased postvoid residual volumes, and urinary tract infection. MUS with BoNT-A injection was insignificantly better than MUS only in urinary incontinence outcome (88% vs. 71%, respectively, p = 0.085) at week three. Among the 33 patients with detrusor overactivity (DO), patients who received BoNT-A had a higher cure rate of incontinence (88% vs. 41%, p = 0.01) and less required antimuscarinic agent or beta-3 agonist (31% vs. 94%, p < 0.001) compared to patients who did not receive BoNT-A injection. There was no significant difference in the incidences of adverse events between two groups. BoNT-A injection with MUS demonstrated efficacy and safety in the treatment of mixed urinary incontinence, specifically for women with DO.

The Efficacy and Safety of Early Postoperative Botulinum Toxin A Injection for Facial Scars

2017 ◽  
Vol 42 (2) ◽  
pp. 530-537 ◽  
Author(s):  
Seo H. Lee ◽  
Hyung J. Min ◽  
Yang W. Kim ◽  
Young W. Cheon
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Efficacy And Safety ◽  
Toxin A
Sign in / Sign up

Export Citation Format

Share Document